What are Gamma Secretase Inhibitor [EPC] drugs?

Gamma Secretase Inhibitor [EPC] drugs are pharmacologic agents that share a common mechanism (typically targeting Gamma-secretase). 1 are currently marketed, with 2 more in clinical development.

What are the marketed Gamma Secretase Inhibitor [EPC] drugs?

Marketed Gamma Secretase Inhibitor [EPC] drugs include Ogsiveo.

Gamma Secretase Inhibitor [EPC]

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 2 in Phase 3

This page covers all Gamma Secretase Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Gamma-secretase, Gamma-secretase complex (PSEN1/PSEN2).

Targets

Gamma-secretase · Gamma-secretase complex (PSEN1/PSEN2)

Marketed (1)

Ogsiveo · Springworks · Oncology
Nirogacestat works by blocking the gamma secretase enzyme, which is involved in the development and progression of desmoid tumors.

Phase 3 pipeline (2)

LY450139 · Eli Lilly and Company · Neurology
LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.
Nirogacestat oral tablet · SpringWorks Therapeutics, Inc. · Oncology
Nirogacestat inhibits gamma-secretase, reducing the production of Notch intracellular domain and downstream signaling that drives abnormal cell proliferation in desmoid tumors.

Patent intelligence

gamma secretase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates